A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 4, 2005, Pages 569-582

  Léger, Jean Marc ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chronic dysimmune neuropathies; Chronic inflammatory demyelinating polyradiculoneuropathy; IFN 1A; Immunosuppressive treatments; Intravenous immunoglobulins; Multifocal motor neuropathy; Mycophenolate mofetil; Plasma exchanges; Polyneuropathy associated with monoclonal gammopathy of unknown significance

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ASEPTIC NECROSIS; BODY WEIGHT DISORDER; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; DISABILITY; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG COST; DRUG RESPONSE; ELECTROPHYSIOLOGY; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOCHEMISTRY; INFECTION; INSOMNIA; LONG TERM CARE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PLASMAPHERESIS; PSYCHOSIS; RADICULOPATHY; REVIEW; SHORT COURSE THERAPY; STOMACH ULCER; WEIGHT GAIN;

CLINICAL TRIALS; DISEASE MANAGEMENT; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 18144429149     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.4.569     Document Type: Review

References (118)

1. LEGER JM: Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Curr. Opin. Neurol. (1995) 8:359-363.
2. HUGHES RA: Chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. (2001) 50:281-282.
3. SANDER RW, LATOV N: Research criteria for defining patients with CIDP. Neurology (2003) 60(Suppl 3):S8-S55.
4. AUSTIN JH: Recurrent polyneuropathies and their corticosteroid treatment. Brain (1958) 81:157-192.
5. DYCK PJ, LAIS AC, OHTA M, BASTRON JA, OKAZAKI H, GROOVER RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc. (1975) 50:621-651.
6. PRINTAS JW, McLEOD JG: Chronic relapsing polyneuritis. J. Neurol. Sci. (1976) 27:427-458.
7. McCOMBE PA, POLLARD JD, McLEOD JG: Chronic inflammatory demyelinating polyradiculoneuropathy. Brain (1987) 110:1617-1630.
8. BAROHN RJ, KISSEL JT WARMOLTS JR, MENDELL JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch. Neurol. (1989) 46:878-884.
9. MAISONOBE T, CHASSANDE B, VERIN M, JOUNI M, LEGER JM, BOUCHE P: Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiologicalal study of 93 patients. J. Neurol. Neurosurg. Psychiatry (1996) 61:36-42.
10. BOUCHARD C, LACROIX C, PLANTE V et al.: Clinicopathological findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology (1999) 52:498-503.
11. LUNN MPT, MANJI H, CHOUDHARY PP et al.: Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry (1999) 66:269-271.
12. McLEOD JG, POLLARD JD, MACASKILL P et al.: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann. Neurol. (1999) 46:910-913.
13. MYGLAND A, MONSTADT P: Chronic polyneuropathies in Vest-Agder, Norway. Eur J. Neurol. (2001) 8:157-165.
14. AD HOC SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY AIDS TASK FORCE: Research criteria for the diagnosis of CIDP. Neurology (1991) 41:617-618.
15. BROMBERG MB: Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve (1991) 14:968-976.
16. BRIANI C, BRANNAGAN TH, TROJABORG W, LATOV N: Chronic inflammatory demyelinating polyneuropathy. Neuromusc. Disord. (1996) 6:311-325.
17. HUGHES RAC, BENSA S, WILLISON H et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. (2001) 50:195-201.
18. NICOLAS G, MAISONOBE T, LE FORESTIER N et al.: Proposed revised electrophysiologicalal criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve (2002) 25:26-30.
19. THAISETTHAWATKUL P, LOGICIAN EL, HERMANN DE: Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology (2002) 59:1526-1532.
20. VAN DEN BERGH PYK, PIERET F: Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve (2004) 29:565-574.
21. LEGER JM: Treatment of chronic dysimmune polyneuropathies. Transfusion Science (1999) 20:63-67.
22. HUGHES RAC: Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Rev. Neurol. (2002) 158(Cahier 2):6S32-6S36.
23. VAN DOORN PA, GARSSEN MPJ: Treatment of immune neuropathies. Curr. Opin. Neurol. (2002) 15:623-631.
24. ROPPER AH: Current treatments for CIDP. Neurology (2003) 60(Suppl. 3):S16-S22.
25. LEGER JM, VIALA K: Recent requisitions in the treatment of chronic immune-mediated polyneuropathies. Rev. Neurol. (2004) 160:205-210.
26. SAID G: Chronic inflammatory demyelinating polyneuropathy. J. Neurol. (2002) 249:245-253.
27. VALLAT JM, TABARAUD F, MAGY L et al.: Diagnostic value of nerve biopsy for atypical chronic inflammatory demylinating polyneuropathy: evaluation of 8 cases. Muscle Nerve (2003) 27:478-485.
28. KHALILI-SHIRAZI A, ARKINSON P, GREGSON N, HUGHES RAC: Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J. Neuroimmunol. (1993) 46:245-252.
29. GABRIEL CM, GREGSON N, HUGHES RAC: Anti-PMP22 antibodies in patients with inflammatory neuropathy. J. Neuroimmunol. (2000) 104:139-146.
30. YAN WX, ARCHELOS JJ, HARTUNG HP, POLLARD JD: P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculopathy. Ann. Neurol. (2001) 50:286-292.
31. GORSON KC, ROPPER AH, ADELMAN LS, WEINBERG DH: Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2000) 23:37-43.
32. HERMOSILLA E, LAGUENY A, VITAL C et al.: Peripheral neuropathy associated with monclonal IgG of undetermined significance. Clinical, electrophysiological, pathological and therapeutic study of 14 cases. J. Peripher. Nerv. Syst. (1996) 1:139-148.
33. DI TROIA A, CARPO A, MEUCCI N et al.: Clinical features and anti-neural activity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J. Neurol. Sci. (1999) 164:64-71.
34. MAGY L, CHASSANDE B, MAISONOBE T et al.: Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiologicalal study of 15 cases. Eur. J. Neurol. (2003) 10:677-685.
35. CHASSANDE B, LEGER JM, BEN YOUNES-CHENNOUFI A et al.: Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiologicalal features in 40 cases. Muscle Nerve (1998) 21:55-62.
36. OH SJ, JOY JL, KURUOGLU R: Chronic sensory demyelinating neuropathy; chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J. Neurol. Neurosurg. Psychiatry (1992) 55:677-680.
37. RUSSELL LC, LATOV N, SANDER HW et al.: Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J. Periph. Nerv. Syst. (2004) 9:132-137.
38. NOBILE-ORAZIO E: Multifocal motor neuropathy. J. Neuroimmunol. (2001) 115:4-18.
39. LEGER JM: Multifocal motor neuropathy with persistent conduction blocks: 18 years on. Rev. Neurol. (2004) 160:889-898.
40. WORKSHOP REPORT: 79th Enmc International Workshop. Multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands. Muscle Nerve (2001) 11:309-314.
41. OLNEY RK, LEWIS RA, PUTNAM TD, CAMPELLONE JV: Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve (2003) 27:117-121.
42. LEWIS RA, SUMNER AJ, BROWN MJ, ASBURY AK: Multifocal demyelinating neuropathy with persistent conduction block. Neurology (1982) 32:958-964.
43. VIALA K, RENIE T, MAISONOBE T et al.: Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain (2004) 127:2010-2017.
44. KATZ JS, SAPERSTEIN DS, GRONSETH G, AMATO AA, BAROHN RJ: Distal acquired demyelinating symmetric neuropathy. Neurology (2000) 54:615-620.
45. TOYKA KV, GOLD R: The pathogenesis of CIDP. Rationale for treatment with immunomodulatory agents. Neurology (2003) 60(Suppl. 3):S2-S7.
46. SCHMIDT B, TOYKA KV, KIEFER R et al.: Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (1996) 19:474-487.
47. GOLD R, HARTUNG HP, LASSMANN H: T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. (1997) 20:399-404.
48. YUKI N, TAGAWA Y, HANDA S: Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. (1996) 70:1-6.
49. DYCK PJ, O'BRIEN PC, OVIATT KD et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treament. Ann. Neurol. (1982) 11:136-141.
50. MEHNDIRATTA MM, HUGHES RAC: Corticosteroids for chronic inflammatory demyeninating polyradiculoneuropathy (Cochrane Review). Cochrane Database Syst. Rev. 3 (2001) Oxford: Update Software.
51. SABATELLI M, MADIA F, MIGNONA T et al.: Pure motor chronic inflammatory demyelinating polyneuropathy. J. Neurol. (2001) 248:772-777.
52. MOLENAAR DSM, VAN DOORN PA, VERMEULEN M: Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J. Neurol. Neurosurg. Psychiatry (1997) 62:388-390.
53. HEININGER K, LIEBERT UG, TOYKA KV et al.: Chronic inflammatory demyelinating polyradiculoneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin. J. Neurol. Sci. (1984) 66:1-14.
54. DYCK PJ, DAUBE J, O'BRIEN PC et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. (1986) 314:461-465.
55. HAHN AF, BOLTON CF, PILLAY N et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain (1996) 119:1055-1066.
56. KAZATCHKINE M, KAVERI SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. (2001) 345:747-755.
57. VAN DOORN PA, BRAND A, STRENGERS PF, MEULSTEE J, VERMEULEN M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology (1990) 40:209-212.
58. VAN DOORN PA, VERMEULEN M, BRAND A, MULDER PG, BUSCH HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch. Neurol. (1991) 48:217-220.
59. VERMEULEN M, VAN DOORN PA, BRAND A, STRENGERS PF, JENNEKENS FG, BUSCH HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, study. J. Neurol. Neurosurg. Psychiatry (1993) 56:36-39.
60. HAHN AF, BOLTON CF, ZOCHODNE D, FEASBY TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain (1996) 119:1067-1077.
61. MENDELL JR, BAROHN RJ, FREIMER ML et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2001) 56:445-449.
62. DYCK PJ, LITCHY WJ, KRATZ KM et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. (1994) 36:838-845.
63. VAN SCHAIK IN, WINER JB, DE HAAN R, VERMEULEN M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a sytematic review. Lancet Neurol. (2002) 1:491-498.
64. HUGHES RAC, SWAN AV, VAN DOORN PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library Issue 4 (2004) John Wiley & Sons, Ltd, Chichester, UK.
65. MAHATTANAKUL W, CRAWFORD TO, GRIFFIN JW, GOLDSTEIN JM, CORNBLATH DR: Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J. Neurol. Neurosurg. Psychiatry (1996) 60:185-187.
66. BARNETT MH, POLLARD JD, DAVIES L, McLEOD JG: Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve (1998) 21:454-460.
67. GORSON KC, ALLAM G, ROPPER AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology (1997) 48:321-328.
68. KUNTZER T, RADZIWILL AJ, LETTRY-TROUILLAT R et al.: Interferon bêta-1a in chronic inflammatory demyelinating polyneuropathy. Neurology (1999) 53:1364-1365.
69. HADDEN RD, SHARRACK B, BENSA S, SOUDAIN SE, HUGHES RA: Randomized trial of interferon bêta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (1999) 53:57-61.
70. VALLAT JM, HAHN AF, LEGER JM et al.: Interferon bêta-1a as investigational treatment for CIDP. Neurology (2003) 60(Suppl. 3):23-28.
71. ROPPER AH, HUGHES RAC, CROS DP et al.: Design of a dose-ranging study to determine the safety and efficacy of intramuscular interferon bêta-1a when used in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology (2004) 62(2 Suppl. 5):A490-A491 (Abstract).
72. MOWZOON N, SUSSMAN A, BRADLEY WG: Mycophenolate (Cellcept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. (2001) 185:119-122.
73. CHAUDHRY V, CORNBLATH DR, GRIFFIN JW, O'BRIEN R, DRACHMAN DB: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology (2001) 72:440-448.
74. UMAPATHI T, HUGHES RAC: Mycophenolate in treatment-resistent inflammatory neuropathies. Eur J. Neurol. (2002) 9:683-685.
75. GORSON KC, AMATO AA ROPPER AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology (2004) 63:715-717.
76. MERIGGIOLI MN, ROWIN J, RICHMAN JG, LEURGANS S: Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann. NY Acad. Sci. (2003) 998:494-499.
77. SUAREZ-ALMAZOR ME, BELSECK E, SGEA B, WELLS G, TUGWELL P: Methotrexate for treating rheumatoid arthitis. The Cochrane Database of Systematic Reviews (1998) Issue 2.
78. CHIN RL, SHERMAN WH, SANDER HW, HAYS AP, LATOV N: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci (2003) 210:19-21.
79. MERKIES IS, SCHMITZ PI, VAN DER MECHE FG, SAMINJ JP, VAN DOORN PA: Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry (2002) 72:596-601.
80. MERKIES IS, SCHMITZ PI, VAN DER MECHE FG, VAN DOORN PA: Comparison between impairment and disability scales in immune-mediated polyneuropathies. Muscle Nerve (2003) 28:93-100.
81. HOLMAN R, LINDEBOOM R, VERMEULEN M, DE HAAN RJ: The AMC Linear Disability Score project in a population requiring residential care: psychometric properties. Health Qual. Life Outcomes (2004) 2:42.
82. LEGER JM, HAYES TH: Neuropathies associated with monoclonal gammopathy. In: Peripheral Neuropathy. A practical approach to diagnosis and management. Didier Cros (Ed) Lipincott Williams & Wilkins, UK (2001):109-120.
83. NOBILE-ORAZIO E, MEUCCI N, BALDINI L et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain (2000) 123:710-717.
84. NOBILE-ORAZIO E, CARPO M: Neuropathy and monoclonal gammopathy. Curr. Opin. Neurol. (2001) 14:615-620.
85. OKSENHENDLER E, CHEVRET S, LEGER JM, LOUBOUTIN JP, BUSSEL A, BROUET JC for the IGM-ASSOCIATED POLYNEUROPATHY STUDY GROUP: Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J. Neurol. Neurosurg. Psychiatry (1995) 59:243-247.
86. BLUME G, PESTRONK A, GOODNOUGH LT: Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Ann. Neurol. (1995) 45:1577-1580.
87. NOTERMANS NC, LOKHORST HM, FRANSSEN H et al.: Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology (1996) 47:1227-1233.
88. LEGER JM: Intravenous immunoglobulins in paraproteinemic demyelinating neuropathies. In: Intravenous Immunoglobulins in the Third Millenium. MC Dalakas and PJ Späth (Eds.) Parthenon Publishing, New-York, USA (2004) 191-196.
89. WILSON HC, LUNN MP, SCHEY S, HUGHES RA: Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J. Neurol. Neurosurg. Psychiatry (1999) 66:575-580.
90. RENAUD S, GREGOR M, FUHR P et al.: Rituximab in the treatment of anti-MAG associated polyneuropathy. Muscle Nerve (2003) 27:611-615.
91. PESTRONK A, FLORRENCE J, MILLER T et al.: Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry (2003) 74:485-489.
92. DYCK PJ, LOW PA, WINDEBANK AJ et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N. Engl. J. Med. (1991) 325:1482-1486.
93. GORSON KC, ROPPER AH, WEINBERG DH, WEINSTEIN R: Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch. Neurol. (2002) 59:7766-7772.
94. BOUCHE P, MOULONGUET A, BEN YOUNES-CHENOUFFI A et al.: Multifocal motor neuropathy associated with conduction block: a study of 24 patients. J. Neurol. Neurosurg. Psychiatry (1995) 59:38-44.
95. CARPO M, CAPPELLARI A, MORA G et al.: Deterioration of multifocal motor neuropathy after plasma exchange. Neurology (1998) 50:1480-1482.
96. NOBILE-ORAZIO E, CAPPELLARI A, MEUCCI N et al.: Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J. Neurol. Neurosurg. Psychiatry (2002) 6:761-766.
97. AZULAY JP, BLIN O, POUGET J et al.: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology (1994) 44:429-432.
98. VAN DEN BERG LH, KERKHOFF H, OEY PI et al.: Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double-blind, placebo-controlled study. J. Neurol. Neurosurg. Psychiatry (1995) 59:248-252.
99. FEDERICO P, ZOCHDONE DW, HAHN AF, BROWN WF, FEASBY TE: Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled, study. Neurology (2000) 55:1256-1262.
100. LEGER JM, CHASSANDE B, MUSSET L, MEININGER V, BOUCHE P, BAUMANN N: Intravenous immunoglobulin therapy in multifocal motor neuropathy. A double-blind-placebo-controlled study. Brain (2001) 124:145-153.
101. VAN DEN BERG-VOS RM, FRANSSEN H, WOKKE J, VAN ES HW, VAN DEN BERG LH: Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann. Neurol. (2000) 41: 919-926.
102. TAYLOR BV, WRIGHT RA, HARPER CM, DYCK PJ: Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve (2000) 23:900-908.
103. UMAPATHI T, HUGHES RAC, NOBILE-ORAZIO E, LEGER JM: Immunosuppressive treatment for multifocal motor neuropathy (Cochrane Review). In: The Cochrane Library Issue 2 (2002) Oxford: Update Software Ltd.
104. VAN DEN BERG-VOS RM, FRANSSEN H, WOKKE JHJ, VAN DEN BERG LH: Multifocal motor neuropathy: long-term clinical and electrophysiologicalal assessment of intravenous immunoglobulin maintenance treatment. Brain (2002) 125:1875-1886.
105. TERENGHI F, CAPPELLARI A, BERSANO A, CARPO M, BARBIERI S, NOBILE-ORAZIO E: How long is IVIg effective in multifocal motor neuropathy? Neurology (2004) 62:666-668.
106. VUCIC S, BLACK KR, TICK CHONG PS, CROS D: Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology (2004) 63:1264-1269.
107. CHAUDHRY V, CORSE AM, CORNBLATH DR et al.: Multifocal motor neuropathy: response to human immun globulin. Ann. Neurol. (1993) 33:237-242.
108. PESTRONK A: Multifocal motor neuropathy: diagnosis and treatment. Neurology (1998) 51 (Suppl. 5):S22-S24.
109. AZULAY JP, RIHET P, POUGET J et al.: Long-term follow-up of multifocal motor neuropathy with conduction block under treatment. J. Neurol. Neurosurg. Psychiatry (1997) 62:391-394.
110. MEUCCI N, CAPPELLARI A, BARBIERI S et al.: Long-term effect of intravenous immunoglobulin and oral cyclophosphamide in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry (1997) 63:765-769.
111. MARTINA ISJ, VAN DOORN PA, SCHMITZ PIM et al.: Chronic motor neuropathies: response to interferon bêta 1a after failure of conventional therapies. J. Neurol. Neurosurg. Psychiatry (1999) 66:197-201.
112. ROJAS-GARCIA R, GALLARDO E, DE ANDRES I et al.: Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology (2004) 61:1814-1816.
113. RUEGG SJ, FUHR P, STECK AJ: Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology (2004) 63:2178-2179.
114. SAPERSTEIN DS, AMATO AA, WOLFE GI et al.: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve (1999) 22:560-566.
115. GORSON KC, ROPPER AH, WEINBERG DH: Upper limb predominant, multifocal chonic inflammatory demyelinating polyneuropathy. Muscle Nerve (1999) 22:758-765.
116. VAN DEN BERG-VOS RM, VAN DEN BERG LH, FRANSSEN H et al.: Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology (2000) 54:26-32.
117. LEGER JM: Usefulness of electrophysiology in the follow-up of dysimmune polyneuropathies. Rev. Med. Liege (2004) 59(Suppl.):124-132.
118. BLOMKWIST P, HUGHES RAC, ILLA I et al.: 129th ENMC International Workshop: Clinical trials for chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy. Neuromusc. Disord. (2005) (In press).